NZ623643A - Meloxicam based formulations for providing analgesia in sheep - Google Patents
Meloxicam based formulations for providing analgesia in sheep Download PDFInfo
- Publication number
- NZ623643A NZ623643A NZ623643A NZ62364312A NZ623643A NZ 623643 A NZ623643 A NZ 623643A NZ 623643 A NZ623643 A NZ 623643A NZ 62364312 A NZ62364312 A NZ 62364312A NZ 623643 A NZ623643 A NZ 623643A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sheep
- meloxicam
- formulations provided
- administered
- salt
- Prior art date
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title abstract 7
- 241001494479 Pecora Species 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 5
- 229960001929 meloxicam Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000036592 analgesia Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000006193 liquid solution Substances 0.000 abstract 1
- 239000006194 liquid suspension Substances 0.000 abstract 1
- 238000003032 molecular docking Methods 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure provides a method of using meloxicam to provide analgesia or control inflammation in sheep wherein the method comprises administering the sheep a therapeutically effective amount of a formulation containing pharmacologically acceptable meloxicam or meloxicam salt. More preferably the method involves administering it to sheep undergoing a painful surgical procedure including one or more of: (i) tail docking, (ii) castration, (iii) muiesing. The formulations provided are adapted for administration via the oral and buccal route and preferably administered to the sheep is in the range of 0.25mg/kg to 1.Omg/kg of bodyweight of the sheep. The formulations provided have a concentration of meloxicam or meloxicam salt between 0.25% and 1 % (w/v) which when administered, result in a C max plasma concentration of meloxicam in the sheep of at least 750 mg/ml. The formulations provided include liquid gels, liquid suspensions and liquid solutions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011904233A AU2011904233A0 (en) | 2011-10-14 | Use of meloxicam in the treatment of post operative sheep | |
| PCT/AU2012/001240 WO2013053015A1 (en) | 2011-10-14 | 2012-10-12 | Meloxicam based formulations for providing analgesia in sheep |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ623643A true NZ623643A (en) | 2015-12-24 |
Family
ID=48081273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ623643A NZ623643A (en) | 2011-10-14 | 2012-10-12 | Meloxicam based formulations for providing analgesia in sheep |
Country Status (3)
| Country | Link |
|---|---|
| AU (2) | AU2012323775B2 (en) |
| NZ (1) | NZ623643A (en) |
| WO (1) | WO2013053015A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5577021B2 (en) * | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals |
| EP2015632B1 (en) * | 2006-04-19 | 2015-12-02 | Mist Pharmaceuticals, LLC | Stable hydroalcoholic oral spray formulations and methods |
-
2012
- 2012-10-12 NZ NZ623643A patent/NZ623643A/en unknown
- 2012-10-12 AU AU2012323775A patent/AU2012323775B2/en active Active
- 2012-10-12 WO PCT/AU2012/001240 patent/WO2013053015A1/en active Application Filing
-
2016
- 2016-07-12 AU AU2016101055A patent/AU2016101055B4/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016101055B4 (en) | 2017-04-20 |
| AU2012323775A1 (en) | 2013-08-01 |
| AU2016101055A4 (en) | 2016-08-25 |
| WO2013053015A1 (en) | 2013-04-18 |
| AU2012323775B2 (en) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491285A1 (en) | IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID | |
| MXPA05012538A (en) | Carbostyril derivatives and mood stabilizers for treating mood disorders. | |
| EA201490279A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| BRPI0707235B8 (en) | sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation | |
| MX2010002392A (en) | Improved brimonidine compositions for treating erythema. | |
| MX2009002314A (en) | Pharmaceutical compositions comprising hgh for oral delivery. | |
| NZ702799A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
| CL2011001178A1 (en) | Use of (r) -7-chloro-niquinuclidin-3-1l) senzo [b] thiophene-2-carboxamide or a salt thereof or a pharmaceutical composition comprising it to prepare a useful medication to improve cognition in a patient suffering from Alzheimer's or schizophrenia. | |
| BR112014009910A2 (en) | 1- (5,6-Dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt formulations | |
| EA200870469A1 (en) | NEW, CONTAINING NIMESULIDE, PHARMACEUTICAL COMPOSITIONS WITH LOW DOSE, THEIR RECEPTION AND APPLICATION | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| ATE485037T1 (en) | CANCER TREATMENT USING FTS AND 2-DEOXYGLUCOSE | |
| MX369117B (en) | Selective ep4 receptor agonistic substance for treatment of cancer. | |
| MX2012005689A (en) | Arachidonic acid analogs and methods for analgesic treatment using same. | |
| MY160652A (en) | Pharmaceutical composition for oral administration | |
| MX2018005715A (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer. | |
| HRP20192189T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| BR112012020185A2 (en) | use of oral heparin preparations to treat urinary tract diseases and disorders. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2017 BY PETER MAXWELL + ASSOCIATES Effective date: 20160819 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2018 BY PETER MAXWELL + ASSOCIATES Effective date: 20171005 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2019 BY PETER MAXWELL + ASSOCIATES Effective date: 20180824 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2020 BY PETER MAXWELL + ASSOCIATES Effective date: 20190820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2021 BY PETER MAXWELL + ASSOCIATES Effective date: 20200713 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2022 BY MAXWELLS PATENT + TRADE MARK ATTORNEYS PTY LTD Effective date: 20211011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2023 BY MAXWELLS PATENT + TRADE MARK ATTORNEYS PTY LTD Effective date: 20220725 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2024 BY MAXWELLS PATENT + TRADE MARK ATTORNEYS PTY LTD Effective date: 20231012 |